Q1 FY25 earnings presentation May 8, 2025 © Solventum 2025. All rights reserved. Forward-looking statements and use of document This presentation and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission ("SEC") (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements ...

Exhibit 99.1 Organic sales growth in the quarter reflect positive performance from all segments, primarily driven by the MedSurg and HIS segments. GAAP and adjusted operating income margin declined due to lower gross margins, including the impact from 3M supply agreement mark-up, and an increase in operating expenses related to public company stand-up costs and growth investments. Represents non-GAAP financial measure; see the "Non-GAAP Financial Measures" section for applicable information. 1 1 • Reported ...

Group 1 - Solventum executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on May 13, 2025, at approximately 2:20 p.m. PST in Las Vegas, NV [1] - A live and archived replay of the fireside chat will be available on the company's website [1] Group 2 - Solventum focuses on enabling better, smarter, and safer healthcare to improve lives [2] - The company is characterized as a new entity with a long legacy of creating breakthrough solutions for challenging healthcare issues [2] - Solventum pioneers innovations at the intersection of health, material, and data science to enhance patient outcomes and empower healthcare professionals [2]

Core Viewpoint - Solventum (SOLV) is set to release its first-quarter 2025 results on May 8, with expectations of strong performance driven by strategic initiatives and segment growth, despite margin pressures and ongoing transformation post-spin from 3M [1][2][5]. Financial Performance - The consensus estimate for revenues in the first quarter is $2 billion, with earnings expected at $1.19 per share [2]. - The company reported a trailing four-quarter average earnings surprise of 14.47% and a previous quarter earnings beat of 7.63% [1][2]. Strategic Initiatives - Solventum's performance is anticipated to benefit from the execution of strategic initiatives aimed at business stabilization and long-term growth acceleration [2]. - The company has raised its free cash flow forecast to $450-$550 million, reflecting capital expenditures of $350-$450 million [3]. Segmental Performance - Revenue growth is expected to be driven by the Dental Solutions and Purification and Filtration segments, with notable contributions from new product launches and increased demand [2][3]. - The Health Information Systems (HIS) segment is likely to see growth from the adoption of its revenue cycle management platform, although challenges in clinical productivity solutions may persist [4]. Margin Analysis - Gross margin contracted to 56.2% and operating margin decreased to 20.4% in the previous quarter, with continued pressure expected in the first quarter due to increased expenses from investments and restructuring [5]. - The company's cost control measures, including the Solventum Way initiative, are expected to help mitigate some margin pressures [6]. Corporate Developments - In February, Solventum announced a deal to sell its Purification & Filtration business to Thermo Fischer for $4.1 billion, which is not expected to impact 2025 EPS [7].

ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https: ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Solventum (SOLV) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This health care company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 13.24%.For the last reported quarter, S ...

Core Insights - Solventum Corporation (SOLV) has partnered with SprintRay to introduce a revolutionary solution for digital dentistry, enabling high-quality, same-day dental restorations through advanced 3D printing technology [1][3] - This collaboration aims to enhance dental care by reducing turnaround time and improving the quality of restorations, providing dental professionals with reliable and cost-effective treatment options [2][4] Company Developments - The partnership introduces the first permanent, chairside 3D-printed crown, combining Solventum's expertise in advanced dental materials with SprintRay's 3D printing technology [3] - The initiative focuses on enhancing patient experience and clinical efficiency by minimizing chair time, reducing office visits, and lowering treatment costs [4][5] Industry Prospects - The global digital dentistry market was valued at $6 billion in 2024 and is projected to reach approximately $19.66 billion by 2034, with a CAGR of 12.6% from 2024 to 2034 [6] - Market growth is driven by the return on investment from digital dentistry equipment, efficiency of same-day procedures, and increasing demand for aesthetic treatments [7] Competitive Landscape - Align Technology, Inc. (ALGN) is enhancing its product offerings in orthodontics and dentistry, including new capabilities for its iTero Lumina intraoral scanner [8] - Dentsply Sirona (XRAY) is driving innovation with product developments like the Primescan 2 intraoral scanner and enhancements to the DS Core platform [10][11] - Envista Corporation (NVST) is advancing digital dentistry with new offerings from DEXIS, including a new CBCT platform and the DEXIS Ti2 Sensor [12][13]

Core Insights - Solventum has announced a strategic partnership with SprintRay to enhance its Dental Solutions business, focusing on the development of durable, same-day restorative dental products [1][3][5] - The partnership aims to integrate advanced material science and 3D printing technology to improve dental workflows and patient outcomes [1][4][5] Company Overview - Solventum, formerly known as 3M Health Care, is a leader in dental composites and restorative dentistry, known for its innovative products like Filtek™ and RelyX™ [2][6] - SprintRay specializes in chairside 3D dental printing, providing a platform for various restorative applications [2][5] Partnership Objectives - The collaboration seeks to bring to market the first permanent chairside 3D printed crown, aiming to reduce the number of office visits required for dental procedures [3][4] - The integration of 3D printing technology is expected to streamline dental care, enhance efficiency, and lower treatment costs for patients [4][5] Market Impact - This partnership aligns with Solventum's strategy to focus on growth and digital capabilities, as part of a three-phased plan to enhance its market position [5] - The announcement coincides with Solventum's recognition as a winner of seven Dental Advisor awards in 2024, highlighting its commitment to quality and innovation in dental solutions [5]

Provides 2028 Targets for Revenue Growth, Margin Expansion, and Free Cash Flow ST. PAUL, Minn., March 20, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today hosts its 2025 Investor Day and will outline strategic priorities for the Company, its business segments, and its long-range plan (LRP) to drive growth and value creation. "Solventum has tremendous potential, with attractive businesses, large and growing markets, and highly regarded brands. We have undertaken a significant transformation to unlock the po ...

ST. PAUL, Minn., March 12, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV), formerly 3M Health Care, today announced the launch of the Attest™ eBowie-Dick Test System (eBowie-Dick System), an electronic test card and auto-reader for sterilization testing that eliminates the need for visual interpretation of results and manual documentation. Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance In less than five seconds, the eBowie-Dick System's simple "pass" or "fail" di ...